Hepatitis Testing/Diagnosis Market

Hepatitis Testing/Diagnosis Market by Disease Type (Hepatitis B, Hepatitis C, Other Hepatitis), Technology (ELISA, RDT, PCR, INAAT), End User (Hospitals, Diagnostic Laboratories, Blood Banks), and Region - Global Forecast to 2026

Report Code: MD 6643 Nov, 2021, by marketsandmarkets.com

[181 Pages Report] The global hepatitis testing market is projected to reach USD 3.6 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 4.7% during the forecast period. The growth of the global hepatitis testing market is being driven by factors such as the high burden of hepatitis, increasing blood transfusion and donations, benefits of POC instruments and kits, and awareness initiatives on hepatitis. High cost of nucleic acid tests, lack of mandates for nucleic acid tests in developing countries and unfavorable reimbursement scenarios are expected to restrain hepatitis market growth. Emerging markets, rising technological advancements in molecular diagnostics, and growth in the biotechnology and biopharmaceutical industries are expected to offer strong growth opportunities for players in the market. In contrast, changing regulatory landscape, opertationsla barriers and shortage of skilled professionals may challenge market growth to a certain extent. The hepatitis testing market is segmented based on disease type, technology, end user, and region.

Hepatitis Testing/Diagnosis Market

To know about the assumptions considered for the study, Request for Free Sample Report

Upcoming Changes in the Hepatitis Testing/Diagnosis Market Report

  • Changes in the market scope: The current report includes the historical data for the hepatitis testing market.
  • New and improved representation of financial information: The new edition of the report provides updated financial information till 2020 (depending on availability) for each listed company in a graphical representation in a single diagram (instead of multiple tables). This will allow for the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating country/region, and business segment focus in terms of the highest revenue-generating segment.
  • Recent market developments: Recent developments help understand market trends and growth strategies adopted by players in the market. For instance, the number of product launches in this market has increased in the last three years (2018 to 2021).
  • Latest product portfolio: The new edition of the report provides an updated product portfolio of the companies profiled in the report.
  • Company profiles: Nine additional company profiles have been added (a total of 20 companies are profiled).
  • Competitive leadership mapping: This edition of the report includes a comprehensive study of companies’ rankings and capabilities. The top vendors in the market have been evaluated in this section. A similar analysis has been conducted for start-ups/SMEs.
  • COVID-19 impact: The current edition of the report covers the COVID-19 impact on the hepatitis testing market. Additional points in the market overview section have been added, keeping in mind the impact of COVID-19 on the market.

COVID-19 Impact on the Hepatitis Testing Market

The COVID-19 outbreak had a negative impact on the hepatitis testing market due to decreasing patient visits to hospitals. The pandemic has put significant strain on healthcare systems. Healthcare institutes and providers were instructed to stop performing elective surgical procedures and medical examinations to slow the spread of the disease and conserve healthcare resources for COVID-19 patients. As a result, many hepatitis testing clinical laboratories experienced a rapid decline in testing volume.

According to the American Journal of Preventive Medicine, a significant decline was observed in hepatitis C testing across the US. The results from the research article—Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic—indicated antibody tests for HCV declined by 59% in April 2020 and rebounded to a 6% decline in July 2020. In comparison, HCV RNA-positive tests declined by 62% in March 2020 and 39% in July 2020.

Global Hepatitis Testing Market Dynamics

DRIVER: High burden of hepatitis

Hepatitis is a major public health concern with a high prevalence rate worldwide, despite significant improvements in treatment options, vaccination coverage, and public awareness. Of all the hepatitis types, B and C are the most prevalent and contribute toward higher mortality rates. In 2019, an estimated 296 million and 58 million people were living with chronic HBV and chronic HCV infection, respectively. In underdeveloped countries, the prevalence of hepatitis is high as compared to developed countries

RESTRAINT: Lack of mandates for nucleic acid tests in developing countries

In developing and low-resource countries, NAT is not mandatory due to the expensive nature of this test and the requirement of skilled personnel. In India, by 2016, only 58 out of a total of 2,550 (~2%) blood banks performed NAT for hepatitis diagnosis. In many developing countries such as India and China, ELISA is the only mandatory test, which acts as a major inhibitor for the adoption of NAT. In India, blood screening involves serological testing for hepatitis surface antigens; however, there are no mandates for using NAT. As a result, there is a lack of clarity about results among people undergoing hepatitis diagnostic tests, which acts as a restraint for market growth.

OPPORTUNITY: Growth in biotechnology and biopharmaceutical industries

The demand for immunoassay instruments and consumables is high in the biotechnology and biopharmaceutical industries. As a result, the growth of these industries is expected to support the growth of the hepatitis testing market during the forecast period. In these industries, the growth of the end-user base has compelled many companies to launch new products and invest in developing advanced products. This is considered a positive indicator for market growth as immunoassays are applied at many stages— from product development and manufacturing to quality control—in production.

CHALLENGE: Operational barriers

Clinical laboratories across major markets are still evolving; technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as NGS and lab-on-a-chip PCR devices. Laboratory space also needs to be reconfigured to meet the requirements of conducting specific molecular diagnostic tests used for pathogen detection as a means of avoiding cross-contamination and ensuring efficient time management. This results in considerable cost escalation to maintain and operate advanced molecular diagnostic instruments, particularly those capable of handling a single sample type. Furthermore, due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis. However, the shortage of skilled and technically knowledgeable laboratory technicians to operate advanced hepatitis testing products has hindered their overall adoption, particularly in emerging markets.

Hepatitis B segment dominated the Hepatitis testing market in 2020.

Based on disease type, the hepatitis testing market is segmented into hepatitis B, hepatitis C, and other hepatitis diseases (hepatitis A, D, and E). The hepatitis B segment accounted for the largest share of the hepatitis testing market in 2020. Factors such as the rising prevalence of hepatitis B, availability of a large number of hepatitis B diagnostic tests, and the increasing adoption of nucleic acid tests for HBV diagnosis are driving the growth of this market segment.

The ELISA segment to witness the highest market share during the forecast period.

Based on technology, the hepatitis testing market is segmented into enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests, polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), and other technologies (such as sequencing, mass spectrometry, and western blotting). The ELISA segment accounted for the largest share of the hepatitis testing market in 2020. The large share of this segment can primarily be attributed to the wide acceptance of this test in clinical practices to diagnose hepatitis.

North America was the largest regional market for hepatitis testing market in 2020.

The global hepatitis testing market is segmented into North America (the US and Canada), Europe (Germany, the UK, and the Rest of Europe), Asia Pacific, and Rest of the World. In 2020, North America dominates the global market, and this trend is expected to continue during the forecast period. The large share and high growth of this region can be attributed to the rising prevalence of hepatitis and increased research and clinical trials for hepatitis testing in the US.

Hepatitis Testing/Diagnosis Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

The prominent players operating in this market include Abbott Laboratories (US), F. Hoffmann La Roche Ltd. (Switzerland), and Siemens Healthineers AG (Germany).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2019

Forecast period

2021–2026

Forecast units

Value (USD)

Segments covered

Disease Type, Technology, End User and Region

Geographies covered

North America, Europe, Asia Pacific, and the Rest of the World

Companies covered

F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (US), Danaher Corporation (US), QIAGEN (Netherlands), bioMιrieux SA (France), DiaSorin S.P.A. (Italy), Ortho Clinical Diagnostics (US), MedMira Inc. (Canada), Fujirebio US, Inc. (Japan), Grifols, S.A. (Spain), Orasure Technologies (US), GenMark Diagnostics Inc. (US), Vela Diagnostics (Singapore), Epitope Diagnostics (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), geneOmbio Technologies Pvt. Ltd. (India), and Molbio Diagnostics Pvt. Ltd. (India).

This report categorizes the hepatitis testing market into the following segments and subsegments:

By Disease Type

  • Hepatitis B (HBV)
  • Hepatitis C (HCV)
  • Other Hepatitis Diseases

By Technology

  • Enzyme-linked Immunosorbent Assay (ELISA)
  • Rapid Diagnostic Tests (RDT)
  • Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Other Technologies

By End User

  • Hospital & Diagnostic Laboratries
  • Blood Banks
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • Rest of Europe
  • Asia Pacific
  • Rest of the World

Recent Developments

  • In 2021, Abbott received FDA Emergency Use Authorization (EUA) for the Alinity m Resp-4-Plex assay.
  • In 2021, F.Hoffmann-La Roche Ltd. acquired GenMark Diagnostics (US) which aimed at adding more products to Roche’s molecular diagnostics portfolio and the global distribution of products offered by GenMark Diagnostics.
  • In 2021, Bio-Rad Laboratories, Inc. partnered with Seegene, Inc. (South Korea). The partnership aims at collaborative development and the commercialization of infectious disease diagnostic products.
  • In 2020, Vela Diagnostics launched an NGS-based test used in the detection of HIV-1, HCV, HBV, and CMV.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 25)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    1.3 MARKET SCOPE
           FIGURE 1 HEPATITIS TESTING MARKET SEGMENTATION
           1.3.1 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 29)
    2.1 RESEARCH DATA
           FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key industry insights
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
           2.2.1 GROWTH FORECAST
                    FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
                    FIGURE 7 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS
    2.5 ASSUMPTIONS FOR THE STUDY
           2.5.1 COVID-19-SPECIFIC ASSUMPTIONS
    2.6 LIMITATIONS
    2.7 RISK ASSESSMENT
    2.8 COVID-19 ECONOMIC ASSESSMENT
    2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY (Page No. - 42)
    FIGURE 11 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 HEPATITIS TESTING MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 HEPATITIS TESTING MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 45)
    4.1 HEPATITIS TESTING MARKET OVERVIEW
           FIGURE 15 HIGH BURDEN OF HEPATITIS TO DRIVE MARKET GROWTH
    4.2 HEPATITIS TESTING MARKET, BY TECHNOLOGY (2021–2026)
           FIGURE 16 RAPID DIAGNOSTIC TESTS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
    4.3 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE AND COUNTRY (2020)
           FIGURE 17 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN HEPATITIS TESTING MARKET IN 2020
    4.4 HEPATITIS TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 18 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 48)
    5.1 INTRODUCTION
           FIGURE 19 HEPATITIS TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
                    5.2.1.1 High burden of hepatitis
                               TABLE 1 HEPATITIS PREVALENCE, BY REGION, 2019 (MILLION)
                    5.2.1.2 Increasing blood transfusion and donations
                               TABLE 2 AVERAGE PREVALENCE OF HEPATITIS INFECTION IN BLOOD DONATIONS, BY INCOME GROUP
                    5.2.1.3 Benefits of POC instruments and kits
                    5.2.1.4 Awareness initiatives on hepatitis
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of nucleic acid tests
                    5.2.2.2 Lack of mandates for nucleic acid tests in developing countries
                    5.2.2.3 Unfavorable reimbursement scenario
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging markets
                    5.2.3.2 Rising technological advancements in molecular diagnostics
                    5.2.3.3 Growth in the biotechnology and biopharmaceutical industries
           5.2.4 CHALLENGES
                    5.2.4.1 Changing regulatory landscape
                    5.2.4.2 Operational barriers
                    5.2.4.3 Shortage of skilled professionals
    5.3 COVID-19 IMPACT ON THE HEPATITIS TESTING MARKET

6 HEPATITIS TESTING MARKET, BY DISEASE TYPE (Page No. - 55)
    6.1 INTRODUCTION
           TABLE 3 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)
           TABLE 4 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)
    6.2 HEPATITIS B (HBV)
           6.2.1 HEPATITIS B SEGMENT TO HOLD THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD
                    TABLE 5 HEPATITIS B CHRONIC INFECTIONS IN THE WESTERN PACIFIC REGION, 2019
                    TABLE 6 HEPATITIS B TESTING MARKET, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 7 HEPATITIS B TESTING MARKET, BY REGION, 2021–2026 (USD MILLION)
                    TABLE 8 NORTH AMERICA: HEPATITIS B TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 9 NORTH AMERICA: HEPATITIS B TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
                    TABLE 10 EUROPE: HEPATITIS B TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 11 EUROPE: HEPATITIS B TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
    6.3 HEPATITIS C (HCV)
           6.3.1 GOVERNMENT INITIATIVES FOR SUPPORTING HCV DIAGNOSIS TO DRIVE MARKET GROWTH
                    TABLE 12 HEPATITIS C CHRONIC INFECTIONS IN THE WESTERN PACIFIC REGION, 2019
                    TABLE 13 HEPATITIS C TESTING MARKET, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 14 HEPATITIS C TESTING MARKET, BY REGION, 2021–2026 (USD MILLION)
                    TABLE 15 NORTH AMERICA: HEPATITIS C TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 16 NORTH AMERICA: HEPATITIS C TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
                    TABLE 17 EUROPE: HEPATITIS C TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 18 EUROPE: HEPATITIS C TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
    6.4 OTHER HEPATITIS DISEASES
           TABLE 19 REP0RTED HEPATITIS A CASES IN THE US SINCE 2016
           TABLE 20 OTHER HEPATITIS DISEASE TESTING MARKET, BY REGION, 2018–2020 (USD MILLION)
           TABLE 21 OTHER HEPATITIS DISEASE TESTING MARKET, BY REGION, 2021–2026 (USD MILLION)
           TABLE 22 NORTH AMERICA: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
           TABLE 23 NORTH AMERICA: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
           TABLE 24 EUROPE: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
           TABLE 25 EUROPE: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)

7 HEPATITIS TESTING MARKET, BY TECHNOLOGY (Page No. - 65)
    7.1 INTRODUCTION
           TABLE 26 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
           TABLE 27 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
    7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
           7.2.1 ELISA IS WIDELY USED FOR THE DETECTION OF HEPATITIS
                    TABLE 28 HEPATITIS TESTING MARKET FOR ELISA, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 29 HEPATITIS TESTING MARKET FOR ELISA, BY REGION, 2021–2026 (USD MILLION)
                    TABLE 30 NORTH AMERICA: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 31 NORTH AMERICA: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2021–2026 (USD MILLION)
                    TABLE 32 EUROPE: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 33 EUROPE: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2021–2026 (USD MILLION)
    7.3 RAPID DIAGNOSTIC TESTS (RDT)
           7.3.1 RAPID TESTS ARE HIGHLY USEFUL IN COUNTRIES WITH LIMITED ACCESSIBILITY TO SOPHISTICATED TECHNOLOGIES
                    TABLE 34 HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 35 HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY REGION, 2021–2026 (USD MILLION)
                    TABLE 36 NORTH AMERICA: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 37 NORTH AMERICA: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2021–2026 (USD MILLION)
                    TABLE 38 EUROPE: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 39 EUROPE: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2021–2026 (USD MILLION)
    7.4 POLYMERASE CHAIN REACTION (PCR)
           7.4.1 PCR TECHNOLOGY IS USED IN CONFIRMATORY TESTS FOR HEPATITIS DIAGNOSIS
                    TABLE 40 HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 41 HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2026 (USD MILLION)
                    TABLE 42 NORTH AMERICA: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 43 NORTH AMERICA: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021–2026 (USD MILLION)
                    TABLE 44 EUROPE: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 45 EUROPE: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021–2026 (USD MILLION)
    7.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
           7.5.1 COST-BENEFITS OF INAAT ARE DRIVING THE GROWTH OF THIS MARKET SEGMENT
                    TABLE 46 HEPATITIS TESTING MARKET FOR INAAT, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 47 HEPATITIS TESTING MARKET FOR INAAT, BY REGION, 2021–2026 (USD MILLION)
                    TABLE 48 NORTH AMERICA: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 49 NORTH AMERICA: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2021–2026 (USD MILLION)
                    TABLE 50 EUROPE: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 51 EUROPE: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2021–2026 (USD MILLION)
    7.6 OTHER TECHNOLOGIES
                    TABLE 52 HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 53 HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2026 (USD MILLION)
                    TABLE 54 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 55 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2026 (USD MILLION)
                    TABLE 56 EUROPE: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 57 EUROPE: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2026 (USD MILLION)

8 HEPATITIS TESTING MARKET, BY END USER (Page No. - 80)
    8.1 INTRODUCTION
           TABLE 58 HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)
           TABLE 59 HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)
    8.2 HOSPITAL & DIAGNOSTIC LABORATORIES
           8.2.1 HOSPITAL & DIAGNOSTIC LABORATORIES ARE THE LARGEST END USERS OF HEPATITIS TESTING PRODUCTS
                    TABLE 60 HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 61 HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 2021–2026 (USD MILLION)
                    TABLE 62 NORTH AMERICA: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 63 NORTH AMERICA: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2026 (USD MILLION)
                    TABLE 64 EUROPE: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 65 EUROPE: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2026 (USD MILLION)
    8.3 BLOOD BANKS
           8.3.1 INCREASING NUMBER OF BLOOD DONATIONS TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
                    TABLE 66 HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY REGION, 2018–2020 (USD MILLION)
                    TABLE 67 HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY REGION, 2021–2026 (USD MILLION)
                    TABLE 68 NORTH AMERICA: HEPATITIS TESTING MARKET FOR BLOOD BANKS,  BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 69 NORTH AMERICA: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2026 (USD MILLION)
                    TABLE 70 EUROPE: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2018–2020 (USD MILLION)
                    TABLE 71 EUROPE: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2026 (USD MILLION)
    8.4 OTHER END USERS
           TABLE 72 HEPATITIS TESTING MARKET FOR OTHER END USERS, BY REGION, 2018–2020 (USD MILLION)
           TABLE 73 HEPATITIS TESTING MARKET FOR OTHER END USERS, BY REGION, 2021–2026 (USD MILLION)
           TABLE 74 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2020 (USD MILLION)
           TABLE 75 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2026 (USD MILLION)
           TABLE 76 EUROPE: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2020 (USD MILLION)
           TABLE 77 EUROPE: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2026 (USD MILLION)

9 EPATITIS TESTING MARKET, BY REGION (Page No. - 89)
    9.1 INTRODUCTION
           TABLE 78 GLOBAL: HEPATITIS TESTING MARKET, BY REGION, 2018–2020 (USD MILLION)
           TABLE 79 GLOBAL: HEPATITIS TESTING MARKET, BY REGION, 2021–2026 (USD MILLION)
    9.2 NORTH AMERICA
           FIGURE 20 NORTH AMERICA: HEPATITIS TESTING MARKET SNAPSHOT
           TABLE 80 NORTH AMERICA: HEPATITIS TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
           TABLE 81 NORTH AMERICA: HEPATITIS TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
           TABLE 82 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)
           TABLE 83 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)
           TABLE 84 NORTH AMERICA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
           TABLE 85 NORTH AMERICA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
           TABLE 86 NORTH AMERICA: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)
           TABLE 87 NORTH AMERICA: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)
           9.2.1 US
                    9.2.1.1 High healthcare expenditure to drive market growth in the US
                               TABLE 88 US: NUMBER OF HEPATITIS A CASES REPORTED, 2015 VS. 2019
                               TABLE 89 HEPATITIS A PREVALENCE RATE PER 100,000 POPULATION IN THE US, 2013–2017
                               TABLE 90 US: KEY MACROINDICATORS
                               TABLE 91 US: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)
                               TABLE 92 US: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)
                               TABLE 93 US: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                               TABLE 94 US: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                               TABLE 95 US: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)
                               TABLE 96 US: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Favorable government initiatives are expected to boost market growth in Canada
                               TABLE 97 CANADA: KEY MACROINDICATORS
                               TABLE 98 CANADA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)
                               TABLE 99 CANADA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)
                               TABLE 100 CANADA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                               TABLE 101 CANADA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                               TABLE 102 CANADA: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)
                               TABLE 103 CANADA: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)
    9.3 EUROPE
           TABLE 104 NUMBER OF HEPATITIS B CASES IN EUROPE, BY COUNTRY, 2014–2018
           TABLE 105 EUROPE: HEPATITIS TESTING MARKET, BY COUNTRY, 2018–2020 (USD MILLION)
           TABLE 106 EUROPE: HEPATITIS TESTING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
           TABLE 107 EUROPE: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)
           TABLE 108 EUROPE: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)
           TABLE 109 EUROPE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
           TABLE 110 EUROPE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
           TABLE 111 EUROPE: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)
           TABLE 112 EUROPE: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Increasing demand for advanced diagnostic technologies to drive market growth in Germany
                               TABLE 113 GERMANY: KEY MACROINDICATORS
                               TABLE 114 GERMANY: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)
                               TABLE 115 GERMANY: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)
                               TABLE 116 GERMANY: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                               TABLE 117 GERMANY: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                               TABLE 118 GERMANY: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)
                               TABLE 119 GERMANY: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 Increasing number of clinical laboratories to drive market growth in the UK
                               TABLE 120 NUMBER OF HEPATITIS C CASES REPORTED IN ENGLAND AND WALES, 2008–2018
                               TABLE 121 UK: KEY MACROINDICATORS
                               TABLE 122 UK: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)
                               TABLE 123 UK: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)
                               TABLE 124 UK: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                               TABLE 125 UK: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                               TABLE 126 UK: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)
                               TABLE 127 UK: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)
           9.3.3 REST OF EUROPE
                    TABLE 128 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP)
                    TABLE 129 ROE: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)
                    TABLE 130 ROE: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)
                    TABLE 131 ROE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                    TABLE 132 ROE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                    TABLE 133 ROE: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)
                    TABLE 134 ROE: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)
    9.4 ASIA PACIFIC
           9.4.1 HIGH PREVALENCE OF HEPATITIS TO BOOST MARKET GROWTH
                    TABLE 135 ASIA PACIFIC: ESTIMATED PREVALENCE OF CHRONIC HBV AND HCV
                    TABLE 136 ASIA PACIFIC: COST COVERAGE FOR THE DIAGNOSIS OF CHRONIC VIRAL HEPATITIS
                    FIGURE 21 ASIA PACIFIC: HEPATITIS TESTING MARKET SNAPSHOT
                    TABLE 137 CHINA: KEY MACROINDICATORS
                    TABLE 138 JAPAN: KEY MACROINDICATORS
                    TABLE 139 INDIA: KEY MACROINDICATORS
                    TABLE 140 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)
                    TABLE 141 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)
                    TABLE 142 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                    TABLE 143 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                    TABLE 144 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)
                    TABLE 145 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)
    9.5 REST OF THE WORLD
           9.5.1 LESS-STRINGENT REGULATIONS FOR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH
                    TABLE 146 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION)
                    TABLE 147 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION)
                    TABLE 148 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION)
                    TABLE 149 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                    TABLE 150 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION)
                    TABLE 151 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 123)
     10.1 OVERVIEW
     10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
               TABLE 152 OVERVIEW OF STRATEGIES ADOPTED BY KEY HEPATITIS TESTING MARKET PLAYERS
     10.3 MARKET SHARE ANALYSIS
               FIGURE 22 HEPATITIS TESTING MARKET SHARE ANALYSIS, 2020
               TABLE 153 HEPATITIS TESTING MARKET: DEGREE OF COMPETITION (2020)
     10.4 COMPANY EVALUATION QUADRANT
             10.4.1 STARS
             10.4.2 EMERGING LEADERS
             10.4.3 PERVASIVE PLAYERS
             10.4.4 PARTICIPANTS
                       FIGURE 23 HEPATITIS TESTING MARKET: COMPANY EVALUATION QUADRANT (2020)
     10.5 COMPANY EVALUATION QUADRANT: SMES/START-UPS
             10.5.1 PROGRESSIVE COMPANIES
             10.5.2 STARTING BLOCKS
             10.5.3 RESPONSIVE COMPANIES
             10.5.4 DYNAMIC COMPANIES
                       FIGURE 24 HEPATITIS TESTING MARKET: COMPANY EVALUATION QUADRANT FOR SMES & START-UPS (2020)
     10.6 COMPETITIVE SCENARIO
             10.6.1 PRODUCT LAUNCHES & APPROVALS
                       TABLE 154 PRODUCT LAUNCHES & APPROVALS
             10.6.2 DEALS
                       TABLE 155 DEALS
             10.6.3 OTHER DEVELOPMENTS
                       TABLE 156 OTHER DEVELOPMENTS
     10.7 COMPANY FOOTPRINT ANALYSIS
               TABLE 157 TECHNOLOGY, DISEASE TYPE, AND REGIONAL FOOTPRINT OF COMPANIES
               TABLE 158 TECHNOLOGY FOOTPRINT OF COMPANIES
               TABLE 159 DISEASE TYPE FOOTPRINT OF COMPANIES
               TABLE 160 REGIONAL FOOTPRINT OF COMPANIES

11 COMPANY PROFILE (Page No. - 135)
     11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weakness/competitive threats)*
             11.1.1 ABBOTT LABORATORIES
                       TABLE 161 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                       FIGURE 25 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
             11.1.2 F. HOFFMANN-LA ROCHE LTD.
                       TABLE 162 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                       FIGURE 26 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
             11.1.3 BIO-RAD LABORATORIES, INC.
                       TABLE 163 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                       FIGURE 27 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
             11.1.4 SIEMENS HEALTHINEERS AG
                       TABLE 164 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
                       FIGURE 28 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2020)
             11.1.5 DIASORIN S.P.A
                       TABLE 165 DIASORIN S.P.A: BUSINESS OVERVIEW
                       FIGURE 29 DIASORIN S.P.A.: COMPANY SNAPSHOT (2020)
             11.1.6 QIAGEN
                       TABLE 166 QIAGEN: BUSINESS OVERVIEW
                       FIGURE 30 QIAGEN: COMPANY SNAPSHOT (2020)
             11.1.7 DANAHER CORPORATION
                       TABLE 167 DANAHER CORPORATION: BUSINESS OVERVIEW
                       FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             11.1.8 GRIFOLS, S.A.
                       TABLE 168 GRIFOLS, S.A.: BUSINESS OVERVIEW
                       FIGURE 32 GRIFOLS, S.A.: COMPANY SNAPSHOT (2020)
             11.1.9 BIOMΙRIEUX SA
                       TABLE 169 BIOMΙRIEUX SA: BUSINESS OVERVIEW
                       FIGURE 33 BIOMΙRIEUX SA: COMPANY SNAPSHOT (2020)
             11.1.10 ORTHO CLINICAL DIAGNOSTICS
                       TABLE 170 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW
                       FIGURE 34 ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT (2020)
     11.2 OTHER PLAYERS
             11.2.1 FUJIREBIO US, INC.
             11.2.2 ORASURE TECHNOLOGIES
             11.2.3 EPITOPE DIAGNOSTICS
             11.2.4 TRIVITRON HEALTHCARE
             11.2.5 MERIL LIFE SCIENCES PVT. LTD.
             11.2.6 GENMARK DIAGNOSTICS INC.
             11.2.7 VELA DIAGNOSTICS
             11.2.8 MOLBIO DIAGNOSTICS PVT. LTD.
             11.2.9 GENEOMBIO TECHNOLOGIES PVT. LTD.
             11.2.10 MEDMIRA INC.

*Details on Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weakness/competitive threats might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 174)
     12.1 INSIGHTS FROM INDUSTRY EXPERTS
     12.2 DISCUSSION GUIDE
     12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.4 AVAILABLE CUSTOMIZATIONS
     12.5 RELATED REPORTS
     12.6 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the hepatitis testing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the hepatitis testing market. The secondary sources used for this study include World Health Organization, World Bank, Centers for Disease Control and Prevention, National Institutes of Health, National Center for Biotechnology Information, United States Department of Health & Human Services (HHS), Association of State and Territorial Health Officials, Association of Asian Pacific Community Health Organizations (AAPCHO), European Diagnostic Manufacturers Association (EDMA), Food and Drug Administration (FDA), Annual Reports, SEC Filings, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Hepatitis Testing/Diagnosis Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the hepatitis testing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the hepatitis testing business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the hepatitis testing market by disease type, technology, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW)
  • To profile the key market players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions; product developments; partnerships, agreements, and collaborations; and expansions in the hepatitis testing market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
Hepatitis Testing/Diagnosis Market Size,  Share & Growth Report
Report Code
MD 6643
Published ON
Nov, 2021
Choose License Type
BUY NOW
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status